p53 negatively regulates the hepatoma growth factor HDGF.
暂无分享,去创建一个
M. Toyota | R. Maruyama | Y. Sasaki | T. Tokino | Tsuyoshi Saito | M. Idogawa | R. Koyama | M. Fujita | M. Kusano | H. Negishi | Ikuko Yokota | H. Suzuki
[1] M. Toyota,et al. p53 Family Members Regulate the Expression of the Apolipoprotein D Gene* , 2009, Journal of Biological Chemistry.
[2] M. Toyota,et al. Identification of Flotillin-2, a Major Protein on Lipid Rafts, as a Novel Target of p53 Family Members , 2008, Molecular Cancer Research.
[3] Sheng-Nan Lu,et al. Hepatoma‐derived growth factor is a novel prognostic factor for gastrointestinal stromal tumors , 2007, International journal of cancer.
[4] M. Toyota,et al. Antitumor effect of adenovirus-mediated p53 family gene transfer on osteosarcoma cell lines , 2007, Cancer biology & therapy.
[5] M. Monden,et al. Hepatoma-Derived Growth Factor Is a Novel Prognostic Factor for Patients with Pancreatic Cancer , 2006, Clinical Cancer Research.
[6] T. Stoops,et al. Hepatoma-Derived Growth Factor Is Expressed after Vascular Injury in the Rat and Stimulates Smooth Muscle Cell Migration , 2006, Pediatric Research.
[7] M. Toyota,et al. Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein–Barr virus , 2006, Cancer.
[8] R. Mantovani,et al. DNA Damage Promotes Histone Deacetylase 4 Nuclear Localization and Repression of G2/M Promoters, via p53 C-terminal Lysines* , 2006, Journal of Biological Chemistry.
[9] M. Monden,et al. Hepatoma-Derived Growth Factor Is a Novel Prognostic Factor for Hepatocellular Carcinoma , 2006, Annals of Surgical Oncology.
[10] Y. Doki,et al. Expression of Hepatoma-Derived Growth Factor Is Correlated with Lymph Node Metastasis and Prognosis of Gastric Carcinoma , 2006, Clinical Cancer Research.
[11] P. Hall,et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[12] Hideji Nakamura,et al. Hepatoma-derived growth factor as a prognostic marker in completely resected non-small-cell lung cancer. , 2005, Oncology reports.
[13] R. Mantovani,et al. Direct p53 Transcriptional Repression: In Vivo Analysis of CCAAT-Containing G2/M Promoters , 2005, Molecular and Cellular Biology.
[14] Edward A Fox,et al. Insights into developmental mechanisms and cancers in the mammalian intestine derived from serial analysis of gene expression and study of the hepatoma-derived growth factor (HDGF) , 2005, Development.
[15] F. Khuri,et al. Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] A. Tucker,et al. Hepatoma-derived growth factor is a pulmonary endothelial cell-expressed angiogenic factor. , 2004, American journal of physiology. Lung cellular and molecular physiology.
[17] I. Kawase,et al. Hepatoma-derived growth factor is involved in lung remodeling by stimulating epithelial growth. , 2004, American journal of respiratory cell and molecular biology.
[18] C. Chen,et al. Diverse cellular transformation capability of overexpressed genes in human hepatocellular carcinoma. , 2004, Biochemical and biophysical research communications.
[19] I. McNeish,et al. Gene Therapy Progress and Prospects: cancer gene therapy using tumour suppressor genes , 2004, Gene Therapy.
[20] I. Kawase,et al. Hepatoma‐derived growth factor induces tumorigenesis in vivo through both direct angiogenic activity and induction of vascular endothelial growth factor , 2003, Cancer science.
[21] I. Kawase,et al. Expression of hepatoma‐derived growth factor in hepatocarcinogenesis , 2003, Journal of gastroenterology and hepatology.
[22] K. Resing,et al. Functional proteomic analysis of melanoma progression. , 2003, Cancer research.
[23] M. Tai,et al. Expression of hepatoma‐derived growth factor in hepatocellular carcinoma , 2003, Cancer.
[24] J. Bushweller,et al. Hepatoma derived growth factor is a nuclear targeted mitogen. , 2003, Current drug targets.
[25] S. Benchimol,et al. Transcriptional repression mediated by the p53 tumour suppressor , 2003, Cell Death and Differentiation.
[26] A. Miyajima,et al. Hepatoma‐derived growth factor is highly expressed in developing liver and promotes fetal hepatocyte proliferation , 2002, Hepatology.
[27] Xin Lu,et al. Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.
[28] Yusuke Nakamura,et al. The p53 Family Member Genes Are Involved in the Notch Signal Pathway* , 2002, The Journal of Biological Chemistry.
[29] Y. Sasaki,et al. Adenovirus-mediated transfer of the p53 family genes, p73 and p51/p63 induces cell cycle arrest and apoptosis in colorectal cancer cell lines: potential application to gene therapy of colorectal cancer , 2001, Gene Therapy.
[30] R. A. Johnson,et al. Transcriptional Repression by p53 through Direct Binding to a Novel DNA Element* 210 , 2001, The Journal of Biological Chemistry.
[31] A. Levine,et al. Surfing the p53 network , 2000, Nature.
[32] Hideji Nakamura,et al. Hepatoma-derived growth factor stimulates smooth muscle cell growth and is expressed in vascular development. , 2000, The Journal of clinical investigation.
[33] Y. Nakamura,et al. Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for bystander effect. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[34] T. Liu,et al. Bystander effect in the adenovirus-mediated wild-type p53 gene therapy model of human squamous cell carcinoma of the head and neck. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[35] Q. Al-Awqati,et al. An endothelial growth factor involved in rat renal development. , 1998, The Journal of clinical investigation.
[36] A. Yang,et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. , 1998, Molecular cell.
[37] Chikashi Ishioka,et al. Cloning and functional analysis of human p51, which structurally and functionally resembles p53 , 1998, Nature Medicine.
[38] L. Ellis,et al. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. , 1998, Cancer research.
[39] S. Schreiber,et al. A role for histone deacetylase activity in HDAC1-mediated transcriptional repression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[40] K. Struhl. Histone acetylation and transcriptional regulatory mechanisms. , 1998, Genes & development.
[41] A. Yang,et al. Monoallelically Expressed Gene Related to p53 at 1p36, a Region Frequently Deleted in Neuroblastoma and Other Human Cancers , 1997, Cell.
[42] S. Stass,et al. Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity. , 1997, Human gene therapy.
[43] T. Kishimoto,et al. Molecular cloning of complementary DNA for a novel human hepatoma-derived growth factor. Its homology with high mobility group-1 protein. , 1994, Journal of Biological Chemistry.
[44] J. Trent,et al. WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.
[45] K. Kinzler,et al. Definition of a consensus binding site for p53 , 1992, Nature Genetics.
[46] J. Sato,et al. Partial purification and characterization of human hepatoma-derived growth factor. , 1989, Clinica chimica acta; international journal of clinical chemistry.
[47] 大嶋 雄一郎. Antitumor effect of adenovirus-mediated p53 family gene transfer on osteosarcoma cell lines , 2007 .
[48] L. Mao,et al. Down-regulation of hepatoma-derived growth factor inhibits anchorage-independent growth and invasion of non-small cell lung cancer cells. , 2006, Cancer research.
[49] Y. Nakamura,et al. The role of p53-target genes in human cancer. , 2000, Critical reviews in oncology/hematology.
[50] J. Levine,et al. Surfing the p53 network , 2000, Nature.
[51] W. El-Deiry,et al. Regulation of p53 downstream genes. , 1998, Seminars in cancer biology.